

# SELECTED PHARMACEUTICALS IN LATE STAGE U.S. AND E.U. DEVELOPMENT OR REGISTRATION as of 4/20/21

Therapeutic Area	Product Name	Indication Sought	U.S. Development Stage	E.U. Development Stage
Cardiovascular and Metabolism	XARELTO® (rivaroxaban)	Infrainguinal revascularized PAD (2) Pediatric VTE (2) COVID-19 MI (PREVENT-HD)	Filed 10/20 Phase III Phase III	
	aprocitentan	Difficult to treat hypertension (2)	Phase III	Phase III
Immunology	TREMFYA® (guselkumab)	Crohn's Disease Pediatric Psoriasis	Phase IIB/III Phase III	Phase IIB/III Phase III
	SIMPONI® (golimumab) nivalimab	UC Monotherapy Pediatric Ulcerative Colitis Warm Autoimmune Hemolytic Anemia	Phase IIB/III Phase III Phase III	Phase IIB/III Phase III Phase III
Infectious Diseases and Vaccines	rilematovir (RSV Fusion Inhibitor)	Hematopoietic Stem Cell Transplantation patients infected with Respiratory Syncytial Virus (FREESIA)	Phase II	Phase II
	VAC52150	Monovalent Ebola Virus Vaccine	Phase III	Approved 7/20
	VAC89220	HIV Px Vaccine	Phase III	Phase III
	VAC31518	Janssen COVID-19 Vaccine	Approved 2/21 EUA	Approved 3/21 cMAA
Neuroscience	SPRAVATO® (esketamine)	Major Depressive Disorder with Acute Suicidal Ideation or Behavior	Approved 7/20	Approved 2/21
	PONVORY™ (ponesimod)	Relapsing Forms of Multiple Sclerosis	Approved 3/21	Filed 3/20
	paliperidone palmitate 6-month seltorexant	Treatment of Schizophrenia Adjunctive treatment for major depressive disorder with insomnia symptoms	Filed 10/20 Phase III	Filed 11/20 Phase III
	DARZALEX® (daratumumab)	Relapsed Refractory MM 1+ prior lines w/PomDex (2) Amyloidosis (AMY 3001) (2) Smoldering multiple myeloma (SMM3001) (2) Frontline multiple myeloma transplant ineligible in combination w/ bortezomib, lenalidomide and dexamethasone (MMY3019, CEPHEUS) (2) Frontline multiple myeloma transplant eligible in combination w/ bortezomib, lenalidomide and dexamethasone (MMY3014, PERSEUS) (2)	Filed 11/20 Approved 1/21 Phase III Phase III	Filed 11/20 Filed 11/20 Phase III Phase III
Oncology	IMBRUVICA® (ibrutinib)	Treatment naïve patients with Mantle Cell Lymphoma in combination with Bendamustine and Rituximab (randomized study MCL-3002) (2) Relapsed/refractory patients with Indolent Non-Hodgkins Lymphoma in combination with Bendamustine and Rituximab or R-CHOP; (randomized study FLR-3001) (2) Frontline Chronic Lymphocytic Leukemia in combination with venetoclax (fixed duration) (GLOW) (2) Relapsed/refractory patients with Mantle Cell Lymphoma in combination with venetoclax (PCYC-1143) (2)	Phase III Phase III Phase III Phase III	Phase III Phase III Phase III Phase III
	ERLEADA® (apalutamide)	Localized prostate cancer High risk prostate cancer (PROTEUS)	Phase III Phase III	Phase III Phase III
	BALVERSA™ (erdafitinib)	Urothelial cancer (2) Tumor Agnostic Non muscle invasive bladder cancer	Phase III Approved 4/19 Phase II Phase II	Phase III Phase III Phase II Phase II
	niraparib	L1 Prostate cancer metastatic castration-resistant in combination with abiraterone acetate and Prednisone	Phase III	Phase III
	niraparib / abiraterone acetate	M1 Metastatic Castration-Sensitive Prostate Cancer in combination with abiraterone acetate and Prednisone	Phase III	Phase III
	ciltacabtagene autoleucl (BCMA CAR-T)	Relapsed refractory multiple myeloma (2) Relapsed refractory multiple myeloma w/1-3 PL (2)	Phase II Phase III	Phase II Phase III
	amivantamab (EGFR/cMET)	Non Small Cell Lung Cancer (2) Frontline Non Small Cell Lung Cancer in combination with chemotherapy	Filed 11/20 Phase III	Filed 11/21 Phase III
	amivantamab / lazertinib	Non Small Cell Lung Cancer (2)	Phase III	Phase III
	teclistamab (BCMA/CD3)	Relapsed refractory multiple myeloma (2)	Phase II	Phase II
	talquetamab (GPRC5D/CD3)	Relapsed refractory multiple myeloma (2)	Phase II	Phase II
Pulmonary Hypertension	RIS/gemcitabine plus cetrelimab	Muscle invasive bladder cancer	Phase III	Phase III
	OPSUMIT® (macitentan)	Fontan-palliated in adolescent (>12 years old) and adult patients Pediatric pulmonary arterial hypertension	Phase III Phase III	Phase III Phase III
	macitentan	Chronic thromboembolic pulmonary hypertension 75mg Pulmonary arterial hypertension 75mg	Phase III Phase III	Phase III Phase III
	UPTRAVI® (selexipag)	Pulmonary arterial hypertension IV Chronic thromboembolic pulmonary hypertension	Phase III Filed 9/20	Phase III Phase III
		Pediatric pulmonary arterial hypertension	Phase III	Phase III
	macitentan w/tadalafil FDC	Pulmonary arterial hypertension	Phase III	Phase III

This information is accurate as of the date hereof to the best of the Company's knowledge. Johnson & Johnson assumes no obligation to update this information.

(2) INVOKANA licensed from Mitsubishi Tanabe Pharma Corporation; Long acting HIV injectable treatment regimen of rilpivirine and cabotegravir developed in collaboration with ViiV Healthcare Ltd; aprocitentan developed in collaboration with Idorsia; XARELTO co-developed with Bayer HealthCare; paliperidone palmitate includes technology licensed from Alkermes, Inc.; DARZALEX licensed from Genmab A/S; IMBRUVICA developed in collaboration with Pharmacocyclos, LLC, an AbbVie company; BALVERSA discovered in collaboration with Astex Pharmaceuticals, Inc.; Niraparib licensed from Tesaro; BCMA CAR-T licensed from Legend Biotech; Monovalent Ebola Vaccine developed in collaboration with Bavarian Nordic A/S, and MVA-BN-Filo® is licensed-in from Bavarian Nordic A/S; DUOBODY platform licensed from Genmab relates to several bispecific antibody programs (Amivantamab, Teclistamab, Talquetamab);

**Janssen Pharmaceutical Companies of Johnson & Johnson**  
**Selected NME Pharmaceutical Pipeline - Recent Approvals/Potential Filings\***  
**(2019-2023 Key Filings, As Outlined at 2019 Pharm Business Review)**  
 Selective Highlights as of April 20, 2021

NMEs APPROVED	NMEs IN REGISTRATION	NME PLANNED FILINGS 2021-2023*	
Oncology	Neuroscience	Oncology	Neuroscience
<b>ERLEADA® (apalutamide) (EU)</b> Non-metastatic prostate cancer  <b>BALVERSA™ (erdafitinib) (US)</b> Urothelial cancer	<b>PONVORY™ (ponesimod) (EU)</b> Monotherapy for multiple sclerosis	<b>niraparib</b> Metastatic castration-resistant prostate cancer (mCRPC)  <b>ciltacabtagene autoleucl (BCMA CAR-T) (EU)</b> Multiple Myeloma	<b>seltorexant</b> Adjunctive treatment for major depressive disorder with insomnia symptoms
<b>Neuroscience</b>	<b>Oncology</b>	<b>BALVERSA™ (erdafitinib) (EU)</b> Urothelial cancer  <b>cusatuzumab</b> Acute myeloid leukemia	<b>Infectious Diseases &amp; Vaccines</b>
<b>SPRAVATO® (esketamine)</b> Treatment resistant depression  <b>PONVORY™ (ponesimod) (US)</b> Relapsing Forms of Multiple Sclerosis	<b>amivantamab (EGFR/cMET)</b> Non Small Cell Lung Cancer  <b>ciltacabtagene autoleucl (BCMA CAR-T) (US)</b> Multiple Myeloma	<b>teclistamab (BCMA/CD3)</b> Multiple myeloma  <b>talquetamab (GPRC5D/CD3)</b> Multiple myeloma	<b>RSV Sr. vaccine</b> RSV vaccine
<b>Infectious Diseases &amp; Vaccines</b>		<b>Immunology</b>	<b>Cardiovascular &amp; Metabolism</b>
<b>Monovalent Ebola Vaccine (EU)</b> Ebola virus Disease  <b>Janssen COVID-19 Vaccine (EUA, cMAA)</b> COVID-19		<b>nipocalimab</b> Warm Autoimmune Hemolytic Anemia	<b>RPGR AAV Gene Therapy</b> X-linked retinitis pigmentosa  <b>aprocitentan</b> Difficult to treat hypertension

\*Filings/approvals assumed to be in the US and EU unless otherwise noted. This information is accurate as of the date hereof to the best of the Company's knowledge. Johnson & Johnson assumes no obligation to update this information. Niraparib licensed from Tesaro; BALVERSA discovered in collaboration with Astex Pharmaceuticals, Inc.; BCMA CAR-T licensed from Legend Biotech; Cusatuzumab licensed from Argenx; Lazertinib licensed from Yuhan Corporation; Retinal assets (Achromatopsia: AAV-CNGA3, AAV-CNGB3) and (X-Linked Retinitis Pigmentosa: AAV-RPGR) licensed from MeiraGTx; DUOBODY platform licensed from Genmab relates to several bispecific antibody programs (Amivantamab, Teclistamab, Talquetamab); Monovalent Ebola Vaccine developed in collaboration with Bavarian Nordic A/S, and MVA-BN-Filo® is licensed-in from Bavarian Nordic A/S.